SAN
DIEGO, Aug. 28, 2024 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Dr. Helen Torley, President and
Chief Executive Officer, and Tram Bui, VP of Investor Relations and
Corporate Communications, are scheduled to present and host
investor meetings at the following investor conferences.
Details of the presentations are as follow:
|
Event:
|
|
|
|
2024 Wells Fargo
Healthcare Conference
|
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
|
Presentation
Date:
|
|
|
|
Wednesday, September 4,
2024
|
|
Presentation
Time:
|
|
|
|
12:00 p.m. PT / 3:00
p.m. ET
|
|
Location:
|
|
|
|
Boston, MA
|
|
|
|
|
|
|
Event:
|
|
|
|
Morgan Stanley
22nd Annual Global Healthcare Conference
|
|
Format:
|
|
|
|
1x1 Meetings
|
|
Date:
|
|
|
|
Thursday, September 5,
2024
|
|
Location:
|
|
|
|
New York, NY
|
|
|
|
|
|
|
Event:
|
H.C. Wainwright 26th
Annual Global Investment Conference
|
|
Format:
|
Fireside Chat and 1x1
Meetings
|
|
Presentation
Date:
|
Tuesday, September 10,
2024
|
|
Presentation
Time:
|
7:00 a.m. PT / 10:00
a.m. ET
|
|
Location:
|
New York, NY
|
A live audio webcast of the presentations will be available in
the Investor Relations section of the Company's website.
Replays of the audio webcast will be available for 90 days
following the conference.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company advancing disruptive
solutions to improve patient experiences and outcomes for emerging
and established therapies. As the innovators of ENHANZE®
drug delivery technology with the proprietary enzyme rHuPH20,
Halozyme's commercially-validated solution is used to facilitate
the subcutaneous delivery of injected drugs and fluids, with the
goal of improving the patient experience with rapid subcutaneous
delivery and reduced treatment burden. Having touched more than
800,000 patient lives in post-marketing use in eight commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Takeda, Pfizer, Janssen,
AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare,
Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technologies that are designed to provide
commercial or functional advantages such as improved convenience,
reliability and tolerability, and enhanced patient comfort and
adherence. The Company has two commercial proprietary products,
Hylenex® and XYOSTED®, partnered commercial
products and ongoing product development programs with several
pharmaceutical companies including Teva Pharmaceuticals and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-302232554.html
SOURCE Halozyme Therapeutics, Inc.
